Notably, CDK6 interference or treatment with the small molecule CDK6 inhibitor palbociclib effectively counteracted the pro-proliferative effect induced by IGF2BP3 while sensitizing bladder cancer cells to cisplatin. Here, CDK6 is linked to urinary bladder cancer.